Allurion stock soars 40% after receiving FDA approval

LootboxPhobia · 2026-02-24T06:04:26+00:00

Allurion Technologies' stock surged 40% after receiving FDA approval for its gastric balloon system, which helps approximately 80 million obese patients in the United States lose weight. The smart capsule is swallowed without surgery and can provide weight loss results within four months. To date, the device has been used to treat over 200,000 patients worldwide, with studies showing significant weight loss effects.

LootboxPhobia

2026-02-24 06:04:26

Abstract generation in progress

Investing.com – Allurion Technologies (NYSE:ALUR) stock surged 40% after the company’s Allurion Gastric Balloon System (including the Allurion Smart Capsule) received FDA approval.

The FDA approved the pre-market approval application for this weight loss device, enabling Allurion to serve approximately 80 million obese Americans with a BMI ranging from 30 to 40 kg/m² (the approved treatment range). The company states that there are over 100 million obese individuals in the U.S.

The Allurion Smart Capsule can be swallowed in a 15-minute outpatient visit, without surgery, endoscopy, or anesthesia. Once in the stomach, the capsule fills with liquid and remains for about four months, helping patients feel full and reduce food intake. After four months, a patented release valve opens, allowing the device to pass naturally. Two months after the first capsule is expelled, another Smart Capsule can be swallowed.

Outside the U.S., the device has been used to treat over 200,000 patients, with results published in more than 30 peer-reviewed medical journals. Data shows that when combined with Allurion’s virtual care suite, patients achieve an overall weight loss of 14%, with over 20% weight loss after two treatment cycles.

The company estimates that about 20 million Americans have started and stopped using GLP-1 medications, with this number expected to grow to 40 million by 2027. Previous studies indicate that 65% of patients discontinue GLP-1 within the first year, mainly due to side effects.

The Allurion Smart Capsule is protected by over 50 patents worldwide, providing approximately four months of treatment per dose, unlike daily or weekly medication regimens.

This article was translated with AI assistance. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.